Tag: Pediatric dermatology

Infantile haemangiomas are the most common benign tumour of infancy, affecting around 1 in 10 children. For problematic cases, oral propranolol is the first-line treatment and can show initial effects remarkably quickly. This guide addresses the central question: **how long does propranolol take to work on haemangioma?**

Infantile hemangiomas affect up to 10% of infants, and topical timolol has emerged as an effective off-label treatment option for certain superficial lesions. However, concerns regarding systemic absorption and potential adverse effects raise a critical question: **is timolol safe for babies**? This guide explores the safety profile, risks, and monitoring requirements associated with its use in infants.

Infantile hemangiomas are the most common tumor of infancy, affecting approximately 4% to 5% of infants [1.7.2, 1.7.5]. For those that require intervention, the primary question is: what medication shrinks hemangiomas effectively and safely? Beta-blockers are now the first-line treatment [1.6.5].

Infantile hemangiomas are the most common benign vascular tumors of infancy, and a topical treatment called timolol is now a first-line therapy for superficial lesions. The timeline for seeing results from this medication can vary, so understanding how long does timolol take to work on hemangioma is key for managing expectations and monitoring progress.

Over the past decade, topical timolol has become a widely used and generally well-tolerated treatment for infantile hemangiomas, with studies showing low rates of adverse events. However, as with any medication, understanding **what are the side effects of timolol eye drops for hemangioma** is crucial for parents and healthcare providers to ensure safe and effective treatment.